Retinal Degenerations and Dystrophies


5


Retinal Degenerations and Dystrophies


RETINITIS PIGMENTOSA


Tomas S. Aleman, MD



  • Molecularly heterogeneous group of inherited outer retinal degenerations that causes a bilateral, slowly progressive, pigmentary retinopathy
  • Prevalence: Approximately 1:3500 and inherited in an autosomal recessive, dominant, or X-linked recessive pattern. Mitochondrial inheritance may exist in rare cases.
  • Symptomatic onset typically in early adulthood although presentation can range from preschool years (early-onset retinal degenerations [EORDs]) to late adulthood (late-onset retinal degenerations [L-ORD])
  • Syndromic retinitis pigmentosa (RP) distinguishes patients with confirmed or suspected systemic abnormalities (eg, sensorineural hearing loss, neurologic, and metabolic defects) from patients with only retinal disease [non-syndromic RP])

Signs and Symptoms


Nyctalopia, progressive visual field constriction, and eventually visual acuity loss; visual acuity is minimally impaired initially


Exam Findings


Initial grayish appearance of retinal pigment epithelium (RPE) with or without white spotted lesions; mid-peripheral, annular-like, pigmentary retinopathy later develops that expands both centripetally and centrifugally with age; waxy appearance to optic nerve and arteriolar attenuation with progression; vitreous cells may be present; end-stage disease characterized by diffuse pigmentary retinopathy with a depigmented or atrophic macula and total vision loss; posterior subcapsular cataracts in > 50%; cystoid macular edema (CME) may develop and epiretinal membranes are common (Figure 5-1A)


Testing



  • Kinetic perimetry (Goldmann): mid-peripheral scotomas, generalized constriction with variable peripheral remnants of vision
  • Color vision: preserved early on, tritan defects and multiple axis of confusion later in disease
  • Short-wavelength fundus autofluorescence (AF) imaging: central islands of normal AF separated from peripheral regions of hypoautofluorescence by narrow hyperautofluorescence rings (Figure 5-1B)
  • Optical coherence tomography (OCT): localized or diffuse photoreceptor outer segment loss and outer nuclear layer (ONL) thinning; total retinal thinning may be masked by a thickened inner retina due to remodeling (Figure 5-1C)
  • Fluorescein angiography (FA): window defects from RPE loss; non-leaking CME; infrequently, choroidal neovascularization (CNV)
  • Electroretinography (ERG): abnormally reduced amplitudes with a rod > cone dysfunction


art


Figure 5-1. (A) Composite fundus picture of patient with typical RP showing bone spicule pigmentation in an annulus in the near mid-periphery. (B) Short-wavelength fundus AF shows signal limited to a central island with scalloped boundaries. (C) OCT cross-section through the fovea shows ONL thinning (*), loss of the outer retinal sublaminae (arrow), and overall retinal thinning.


Differential Diagnosis


Cone dysfunctions and cone-rod dystrophies; congenital stationary night blindness, fundus albipunctatus, retinitis punctata albescens, severe Stargardt disease; choroidal dystrophies (choroideremia, gyrate atrophy, Bietti’s crystalline dystrophy, central areolar and dystrophies, helicoidal); carrier state of inherited retinal degenerations (IRD; X-linked RP, choroideremia); hereditary vitreoretinopathies (familial exudative vitreoretinopathy, Wagner and Stickler syndromes); autoimmune retinopathies; acute zonal occult outer retinopathy (AZOOR); post-infectious or post-inflammatory pigmentary retinopathies (pars planitis, birdshot chorioretinopathy, serpiginous retinopathy, multifocal placoid pigment epitheliopathy, sarcoidosis, rubella, syphilis, toxocara); vitamin A deficiency and abetalipoproteinemia; toxic retinopathies (thioridazine, chloroquine); neuro-ophthalmic diseases with inner retinal and visual field loss


Management



  • Vitamin A palmitate: hyper-supplementation at 10,000 IU may slow progression; obtain clearance from primary care provider with monitoring for liver toxicity
  • Docosahexaenoic acid (DHA): 400 mg by mouth 3 times a day
  • Treatment of CME: topical and/or systemic carbonic anhydrase inhibitors (CAI) are first choice (eg, dorzolamide, brinzolamide); topical, periocular, or intravitreal steroids have a role if CAI and nonsteroidal anti-inflammatory drugs fail; anti-vascular endothelial growth factor (VEGF) injections may be used as a last resort
  • Epiretinal electronic implants (Argus II [Second Sight]) approved by the Food and Drug Administration for end-stage disease with bare light perception or worse vision

CONE DYSTROPHIES


Tomas S. Aleman, MD



Signs and Symptoms


Typically present as infants or toddlers with nystagmus, photophobia and poor color discrimination and visual acuity; may also present later in life and into adulthood


Exam Findings


Fundus exam normal or blunted foveal reflex; may have small areas of depigmentation in and around foveal center; foveal atrophy occurs rarely (Figure 5-2A)


Testing



  • Kinetic perimetry (Goldmann): fields mostly full or show mild generalized constriction
  • Color vision: severely abnormal
  • Full-field sensitivity testing (FST): normal rod-mediated sensitivities, severely abnormal cone vision
  • Short-wavelength fundus AF imaging: preserved although may have central hypoautofluorescence in forms with more severe central disease (Figure 5-2B)
  • OCT: foveal hypoplasia in some; foveal thinning with shortening and loss of the cone photoreceptor outer segment mainly at fovea (Figure 5-2C)
  • ERG: normal rod function, cone ERGs are extremely reduced in amplitude to undetectable


art


Figure 5-2. (A) Fundus photo of a patient with cone-rod dystrophy. (B) Near infrared AF demonstrating dense loss of RPE melanin centrally and diffuse loss into near mid-periphery. (C) Spectral domain-OCT vertical cross-section through the fovea shows severe ONL loss at the fovea with increased posterior backscattering and ONL preservation (arrow) in the peripapillary retina in this ABCA4-CRD patient.


Differential Diagnosis


Cone-rod dystrophies, Leber congenital amaurosis, neuronal ceroid lipofuscinoses, neuro-ophthalmic diseases with inner retinal and vision loss


Management



STARGARDT DISEASE


Tomas S. Aleman, MD



  • Most frequent juvenile macular dystrophy with a prevalence of ~1:10,000 and onset typically in adolescence
  • Typically autosomal recessive and associated with ABCA4 gene mutations
  • Onset and severity variable with milder forms showing adult onset and relative foveal preservation without atrophy termed fundus flavimaculatus (FFM)

Signs and Symptoms


Vision loss, impaired color vision


Exam Findings


Normal or blunted foveal reflex in early stages; variable central depigmentation and atrophy with a tapetal or beaten bronze sheen; pisciform whitish-yellow flecks distributed as an annulus around center and into mid-periphery which expand centripetally while most central lesions fade into central RPE atrophy (Figure 5-3A)


Testing



  • Kinetic perimetry (Goldmann): fields are full peripherally with variable central scotomas depending on stage
  • Static perimetry: central scotomas
  • Color vision: normal in early disease, abnormal in later stages


art


Figure 5-3. (A) Color fundus image of a patient with Stargardt disease showing characteristic yellow pisciform flecks. (B) Fundus AF showing areas of hypoautofluorescence in areas of RPE atrophy and hyperautofluorescence of flecks. (C) Spectral domain-OCT reveals loss of the ONL and ellipsoid zone (between arrows) in the fovea. The ONL (*) is intact outside the fovea.

Stay updated, free articles. Join our Telegram channel

Nov 28, 2021 | Posted by in OPHTHALMOLOGY | Comments Off on Retinal Degenerations and Dystrophies

Full access? Get Clinical Tree

Get Clinical Tree app for offline access